S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:BNTX

BioNTech Stock Forecast, Price & News

$278.34
-8.02 (-2.80 %)
(As of 10/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$268.05
$295.82
50-Day Range
$236.14
$416.50
52-Week Range
$75.35
$464.00
Volume3.56 million shs
Average Volume3.07 million shs
Market Capitalization$67.50 billion
P/E Ratio14.57
Dividend YieldN/A
Beta-1.59
30 days | 90 days | 365 days | Advanced Chart
Receive BNTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.


BioNTech logo

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTX
Phone
N/A
Employees
2,020
Year Founded
2008

Sales & Book Value

Annual Sales
$550.91 million
Cash Flow
$0.22 per share
Book Value
$6.93 per share

Profitability

Net Income
$17.36 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$67.50 billion
Next Earnings Date
11/9/2021 (Confirmed)
Optionable
Not Optionable

Social Links


MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

1080th out of 1,359 stocks

Biological Products, Except Diagnostic Industry

163rd out of 196 stocks

Analyst Opinion: 2.1Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












BioNTech (NASDAQ:BNTX) Frequently Asked Questions

Is BioNTech a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BioNTech stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View analyst ratings for BioNTech
or view top-rated stocks.

What stocks does MarketBeat like better than BioNTech?

Wall Street analysts have given BioNTech a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioNTech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioNTech's next earnings date?

BioNTech is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for BioNTech
.

How can I listen to BioNTech's earnings call?

BioNTech will be holding an earnings conference call on Tuesday, November 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) posted its quarterly earnings data on Sunday, August, 8th. The company reported $10.77 EPS for the quarter, beating the consensus estimate of $8.35 by $2.42. The company earned $5.31 billion during the quarter, compared to analyst estimates of $3.27 billion. BioNTech had a trailing twelve-month return on equity of 159.73% and a net margin of 52.48%. BioNTech's revenue was up 12599.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.38) earnings per share.
View BioNTech's earnings history
.

How has BioNTech's stock been impacted by Coronavirus (COVID-19)?

BioNTech's stock was trading at $32.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BNTX shares have increased by 765.2% and is now trading at $278.34.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BNTX?

14 analysts have issued 12-month price objectives for BioNTech's shares. Their forecasts range from $104.00 to $433.00. On average, they expect BioNTech's stock price to reach $253.79 in the next year. This suggests that the stock has a possible downside of 8.8%.
View analysts' price targets for BioNTech
or view top-rated stocks among Wall Street analysts.

Who are BioNTech's key executives?

BioNTech's management team includes the following people:
  • Prof. Ugur Sahin M.D., Co-Founder, CEO & Member of Management Board (Age 55, Pay $716.08k)
  • Prof. Christoph Hubert Huber, Co-Founder & Member of Supervisory Board (Age 76)
  • Dr. Sierk Poetting Ph.D., CFO, MD, COO & Member of Management Board (Age 47, Pay $722.01k)
  • Mr. Ryan Richardson, Chief Strategy Officer, MD & Member of Management Board (Age 41, Pay $636.65k)
  • Mr. Sean Marett, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board (Age 55, Pay $799.07k)
  • Dr. Ozlem Tureci, Chief Medical Officer & Member of Management Board (Age 53, Pay $708.97k)
  • Sylke Maas Ph.D., VP of Investor Relations and Bus. Strategy
  • Dr. James Timothy Patrick Ryan Ph.D., VP of Legal & Intellectual Property
  • Michael Boehler, MD & Head of Global External Communications
  • Katalin Kariko, Sr. VP & Head of RNA Protein Replacement

What is Ugur Sahin's approval rating as BioNTech's CEO?

10 employees have rated BioNTech CEO Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among BioNTech's employees.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (2.62%), Redwood Investments LLC (0.01%), Private Advisor Group LLC (0.01%), Pinnacle Associates Ltd. (0.00%), Purus Wealth Management LLC (0.00%) and Kestra Advisory Services LLC (0.00%).

Which major investors are selling BioNTech stock?

BNTX stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., First Midwest Bank Trust Division, Redwood Investments LLC, Wedbush Securities Inc., Hollencrest Capital Management, Purus Wealth Management LLC, and IFP Advisors Inc.

Which major investors are buying BioNTech stock?

BNTX stock was bought by a variety of institutional investors in the last quarter, including XR Securities LLC, Kestra Advisory Services LLC, Mezzasalma Advisors LLC, Pinnacle Associates Ltd., Capital CS Group LLC, Private Advisor Group LLC, CTC LLC, and DekaBank Deutsche Girozentrale.

How do I buy shares of BioNTech?

Shares of BNTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $278.34.

How much money does BioNTech make?

BioNTech has a market capitalization of $67.50 billion and generates $550.91 million in revenue each year. The company earns $17.36 million in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does BioNTech have?

BioNTech employs 2,020 workers across the globe.

Does BioNTech have any subsidiaries?

The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.

When was BioNTech founded?

BioNTech was founded in 2008.

What is BioNTech's official website?

The official website for BioNTech is www.biontech.de.

Where are BioNTech's headquarters?

BioNTech is headquartered at AN DER GOLDGRUBE 12, MAINZ 2M, 55131.

How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company can be reached via email at [email protected].


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.